EUVIMEDEUVIMED entdecken
Crossref

Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project

Anna Dobrzeniecka iD, Ewa Talarek, Małgorzata Aniszewska, Marta Troszczyńska, Magdalena Marczyńska, Maria Pokorska-Śpiewak

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Anna Dobrzeniecka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Quinoxalines, Benzimidazoles, Sulfonamides. Die Arbeit nennt 29 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In this noncommercial, nonrandomized, open‐label therapeutic program POLAC project, we aimed to analyze the efficacy and safety of the pangenotypic regimen glecaprevir/pibrentasvir (GLE/PIB) in children aged 3–17 years with chronic hepatitis C.

Methods

Eligible patients for 8‐week therapy with GLE/PIB were divided into two age groups. Patients above 12 years of age received tablets containing a fixed dose of 300/120 mg GLE/PIB, and patients below 12 years weighing 12–45 kg were treated with granule formula adjusted to patients' weight. The primary endpoint of the study was treatment efficacy, defined as sustained virologic response at 12 weeks posttreatment (SVR12, undetectable hepatitis C virus (HCV) RNA using a real‐time polymerase chain reaction).

Results

We included 63 patients, 21 received tablets, and 42 received the granules formula. Median age of the patients was 8 years (interquartile range, IQR 6–12). There were 37 (59%) males. Fifty‐nine children (94%) were infected vertically. Most patients (43, 68%) had genotype 1 HCV. Four patients presented with significant fibrosis (F2‐F3 METAVIR) at baseline, but there were no cases of cirrhosis. Sixty‐two patients (98%) achieved SVR12. One patient was lost to follow‐up before SVR12 evaluation; however, at the end of therapy, his HCV RNA levels were undetectable. Thirty‐two patients (51%) had adverse events (AEs). There were 49 AEs possibly related to the treatment, all mild. The most frequent AEs included abdominal pain (14%), fatigue (11%), and pruritus (11%).

Conclusions

Our study confirms that 8 weeks of therapy with GLE/PIB in children with chronic hepatitis C is highly effective and safe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicQuinoxalinesBenzimidazolesSulfonamidesPyrrolidinesAntiviral AgentsHumansChildMaleFemaleAdolescentChild, PreschoolTreatment OutcomeDrug CombinationsLeucineCyclopropanesLactams, MacrocyclicProlineSustained Virologic ResponseAminoisobutyric AcidsHepacivirusDrug Therapy, CombinationPhenylbutyrates

Stichwörter der Autor:innen

direct acting antiviralshepatitis C viruspediatric hepatologysustained virological response

Substanzen

QuinoxalinesBenzimidazolesSulfonamidesPyrrolidinesAntiviral Agentsglecaprevir and pibrentasvirDrug CombinationsglecaprevirLeucineCyclopropanes

Autor:innen und Institutionen

  • Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
  • Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland.

ORCID-Profile: Anna Dobrzeniecka

Förderung

  • None

Zitieren

APA

Dobrzeniecka, A., Talarek, E., Aniszewska, M., Troszczyńska, M., Marczyńska, M., & Pokorska-Śpiewak, M. (2026). Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70241

Vancouver

Dobrzeniecka A, Talarek E, Aniszewska M, Troszczyńska M, Marczyńska M, Pokorska-Śpiewak M. Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70241

BibTeX
@article{Dobrzeniecka2026,
  author = {Dobrzeniecka, Anna and Talarek, Ewa and Aniszewska, Małgorzata and Troszczyńska, Marta and Marczyńska, Magdalena and Pokorska-Śpiewak, Maria},
  title = {Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70241}
}
Kostenlos starten →